

## Δημοσιεύσεις

---

1. N. Κατσιλάμπρος, Φ.Φιλιππίδης, **A. Γαλανόπουλος**, Θ. Πέππας, Λ. Κωφοτζούλη, Ε. Μαγκλάρα, Μ. Φραγκάκη, Π. Σισκούδης, Μ. Μαραγκός, Π. Σφηκάκης. Μεταβολικές επιδράσεις διαφόρων τύπων μακαρονιών σε διαβητικά άτομα τύπου-2. *Materia Medica Greca* 16 (1) 88-92, 1988.
2. M. Kalmanti, Th. Kalmantis, M. Vassilaki, M. Yiagnisis, **A. Galanopoulos**, D.A. Spandidos. Immunohistochemical Analysis of the ras Oncoprotein product p21 in the Bone Marrow of Children with Acute Leukemia. *Genetics of Haematological disorders*, Ch. Bartsocas, D. Loukopoulos, Chapter 16, ed. Hemisphere publishing corporation, 1992.
3. Petrikkos G., Giamarellou H., Kontopidou F., **Galanopoulos A.**, Toskas A., Xefferi E., Karvountzis G., Sfikakis P. Comparative study of the efficacy and tolerability of imipenem-cilastatin versus ceftazidime as initial monotherapy for febrile neutropenic patients. *Therapy of infectious Diseases*, Vol VI, No 3-4 / 1991, p. 322-326.
4. Maria kalmanti, Themistokles Kalmantis, Maria Vassilaki, **Athanasios Galanopoulos**, Demetrios Grenzalias and Demetrios A. Spandidos.  
  
The expression of the Ras p21 Oncoprotein in the Bone Marrow Smears of Children with Acute Leukemia. *Anticancer Research* 12 : 2177- 2180 ,1992.
5. Γ. Στεργίου, Ν. Μαλάμος, Χ. Ματσούκα, **A. Γαλανόπουλος**, Σ. Ασημακόπουλος, Α. Φιλιώτου, Α.Αντωνόπουλος, Α. Καλοταιράκης, Γ.Π. Σταθόπουλος. Πρωτοπαθή μη Hodgkin's λεμφώματα στομάχου και εντέρου. *Ιατρική* 64 (1) : 57- 63 , 1993.
6. **A. Galanopoulos** , E.Kritikou-Griva , J.Gligori , E.Michalis,V.Grigoraki T.Marinakis , J.Kakkas , A.Tasiopoulou ,N.I. Anagnostopoulos  
  
Treatment of patients with myelodysplastic syndrome with amifostine.  
  
*Leuk Res.* 2001; 25 (8) : 665-671.
7. N.Viniou, E. Terpos, **A. Galanopoulos**, E. Kritikou-Griva, S. Akel, E. Michalis, E. Apostolidou, D. Georgiadou, A. Kouraklis, A. Parcharidou, G. Kokkini, A. Symeonidis, N.I.Anagnostopoulos, J.I. Christakis, A.  
  
Tasiopoulou, D. Loukopoulos, X. Yataganas .Treatment of anemia in low risk myelodysplastic syndromes with Amifostine. In vitro testing of response. *Ann Hematol.* 2002 Apr; 81(4):182-6.
8. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, **Galanopoulos A**, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Timiakou M, Zoumbos N, Yataganas X.

- Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. *Leuk Res.* 2002 Feb; 26(2): 143-54.
9. Giannakoulas NC, Karakantza M, Theodorou GL, Pagoni M, **Galanopoulos A**, Kakagianni T, Kouraklis-Symeonidis A, Matsouka P, Maniatis A, Zoumbos NC. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. *Br J Haematol.* 2004 Jan;124(1):97-105
  10. **Γαλανόπουλος Α**, Αναγνωστόπουλος Ν. Η αναιμία της χρόνιας νόσου. *Ιατρική* 2004; 85: 48-54.
  11. Elpiniki Kritikou-Griva, E. Goumakou, S.I. Papadimitriou, A. **Galanopoulos, A**. Leivada, I. Tsurveloudis, A. Tsakiridou, Anagnostopoulos N.I. "Myelodysplastic syndromes with thrombocytosis: a report from a single centre". *Haema* 2004;7(3):352-356.
  12. Eleni Goumakou, Stephanos I.Papadhimitriou, Elpiniki Kritikou-Griva, Theodoros Marinakis, George Paterakis, Ageliki Davea, Anastasia Leivada, **Athanasios Galanopoulos**, Anagnostopoulos N.I.. "The FAB and WHO classification in AML: an analysis from the application in 150 cases". *Haema* 2005; 8(3): 465-472.
  13. Eurydiki Michalis, George Paterakis, Anastasia Leivada, Athanasios Zomas, Lilian Kavalierou, **Athanasios Galanopoulos**, Theodoros Marinakis, Anastasia Skandalis, Konstantina Politi, Anagnostopoulos N.I. "Adult T-cell Leukaemia/lymphoma: a case report". *Haema* 2005; 8(2): 278-281.
  14. Mavrogianni D, Tsaftaridis P, Terpos E, Symeonidis A, **Galanopoulos A**, Papadaki EA, Zoumbos N, Meletis J, Pangalis GA, Viniou N. Macrophage Inflammatory Protein-1 alpha (MIP-1alpha) is over-expressed in a cohort of patients with myelodysplastic syndromes. *Eur J Haematol.* 2005 Jul;75(1):85-6.
  15. Lilakos K, Viniou NA, Mavrogianni D, Vassilakopoulos TP, Dimopoulou MN, Plata E, Angelopoulou MK, Variami E, Stavrogianni N, Liapi D, Xilouri I, **Galanopoulos A**, Ageloudi M, Panayiotidis P, Voulgarelis M, Rombos J, Meletis J, Yataganas X, Pangalis GA. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study. *Anticancer Res.* 2006 Mar-Apr;26(2A):1201-7.
  16. **Galanopoulos AG**, Symeonidis A, Kourakli A, Papadaki EA, Tsaftaridis P, Terpos E, Aktipi A, Roussou P, Protopappa M, Pappaioannou M, Zikos P, Speletas M, Parcharidou A, Laoutaris N, Anagnostopoulos NI, Meletis J, Pangalis GA, Zoumbos N, Viniou N; the Hellenic MDS Study Group. Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group. *Eur J Haematol.* 2007 Jan;78(1):89-90
  17. Xanthopoulos V, **Galanopoulos AG**, Paterakis G, Apessou D, Argyrakos T, Goumakou E, Papadhimitriou SI, Savvidou I, Georgiakaki M, Anagnostopoulos. Intravascular B-cell lymphom with leukemic presentation: case report and literature review. *Eur J Haematol.* 2008 Feb;80(2):177-81.

18. Stavropoulou C, Sambani C, Rigana H, Georgakakos VN, Voutsinas G, Manola KN, Pantelias GE, Makropoulos V, Hellenic MDS Study Group. Low frequency of the glutathione- S- transferase T1- null genotype in patients with primary myelodysplastic syndrome and 5q deletion. *Leukemia* 2008; 28 (8): 1643-6.
19. **Galanopoulos A**, Papadhimitriou S.I, Kritikou-Griva E, Georgiakaki M, Anagnostopoulos NI. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia. *Ann Hematol* 2009; 88 (3):281-2.
20. Ximeri M, **Galanopoulos A**, Klaus M , Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Ponticoglou K, H.Papadaki; on behalf of the Hellenic MDS Study Group. Effect of the lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. *Haematologica* 2010; 95(3): 406-414.
21. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, **Galanopoulos A**, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. *Am J Hematol* 2010 Nov;85(11):894-6.
22. Tsagarakis NJ, Kentrou NA, Kakiopoulos G, Androutsos G, **Galanopoulos A**, Michaelidis C, Rontogianni D, Tolis A, Chini S, Gortzolidis G, Papadimitriou KA, Skoumi D, Tzanetou K, Paterakis G. Flow cytometry as a diagnostic tool in the early diagnosis of aggressive lymphomas mimicking life-threatening infection. *Case Report Med* 2011;2011:743817.
23. Kritikou-Griva E, Spyropoulou-Vlachou M, Tsagarakis NJ, Goumakou E, Vrani V, **Galanopoulos A**, Papadhimitriou SI, Androutsos G, Paterakis G, Stavropoulos-Giokas C. High frequency of human leukocyte antigen class II DRB1\*1602 haplotype in Greek patients with myelodysplastic syndrome and of DRB1\*1501 in the low-risk subgroup. *Hum Immunol.* 2012 Mar;73(3):278-81
24. Diamantopoulos PT, Chatzileonida T, **Galanopoulos A**, Yiakoumis X, Saridaki AM, Angelidis A, Papakostas E, Bazanis E, Sachanas S, Michael M, Pangalis GA, Anagnostopoulos NI, Meletis J, Viniou NA. Leukemic transformation in patients with myelodysplastic syndromes after treatment with granulocyte colony-stimulating factor. *Leuk Lymphoma.* 2012 Oct;53(10):2069-72
25. Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A, Maragkos K, Kontogianni K, Lafioniatis S, Vrettou E, Koutsouka F, Papadakis A, Mihos A, Eftihiadis E, Farmaki K, Papageorgiou O, Tapaki G, Maili P, Theohari M, Drosou M, Kartasis Z, Aggelaki M, Basileiadi A, Adamopoulos I, Lafiatis I, **Galanopoulos A**, Xanthopoulidis G, Dimitriadou E, Mprimi A, Stamatopoulou M, Haile ED, Tsironi M, Anastasiadis A, Kalmanti M, Papadopoulou M, Panori E, Dimoxenou P, Tsirka A, Georgakopoulos D, Drandrakis P, Dionisopoulou D, Ntalamaga A, Davros I, Karagiorga M; Greek Haemoglobinopathies Study Group. A national registry of haemoglobinopathies in Greece: deduced demographics, trends in mortality and affected births. *Ann Hematol.* 2012 Sep;91(9):1451-8
26. Diamantopoulos PT, Kalotychou V, Polonyfi K, Sofotasiou M, Anastasopoulou A, **Galanopoulos A**, Spanakis N, Vassilakopoulos T, Angelopoulou M, Siakantaris M, Variami E, Poziopoulos C, Terpos E, Kollia P, Viniou NA. Correlation of Fc-γ RIIA

- polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas Leuk Lymphoma. 2013 Sep;54(9):2030-4.
27. Papanastasiou L, Pappa T, Dasou A, Kyrodinou E, Kontogeorgos G, Samara C, Bacaracos P, **Galanopoulos A**, Piaditis G. Case report: Primary pituitary non-Hodgkin's lymphoma developed following surgery and radiation of a pituitary macroadenoma. Hormones (Athens). 2012 Oct-Dec;11(4):488-94.
  28. Papadopoulou V, Diamantopoulos PT, Kontandreopoulou E, Polonyfi K, Variami E, Kouzis P, **Galanopoulos A**, Spanakis N, Zervakis K, Iliakis T, Perrea D, Kollia P, Vassilakopoulos TP, Pangalis GA, Kyrtsonis C, Vaiopoulos G, Viniou NA. Evidence for regulation of oxidative stress by latent membrane protein 1 oncoprotein in patients with low-grade leukemic B cell lymphoma with latent Epstein-Barr virus infection. Leuk Lymphoma. 2014 Aug;55(8):1904-9
  29. Diamantopoulos PT, Polonyfi K, Sofotasiou M, Mantzourani M, **Galanopoulos A**, Spanakis N, Papadopoulou V, Kalala F, Iliakis T, Zareifi DS, Kodandreopoulou E, Vassilakopoulos T, Angelopoulou M, Siakantaris M, Terpos E, Variami E, Kollia P, Vaiopoulos G, Pangalis G, Viniou NA. Survivin messenger RNA levels in Epstein-Barr virus-positive patients with leukemic low-grade B-cell lymphomas expressing the latent membrane protein 1: evidence of apoptotic function? Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):56-60.
  30. Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, **Galanopoulos AG**, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, Kotsianidis I. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer J. 2014 Feb 28;4:e187
  31. Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E, Kontakis M, **Galanopoulos A**, Kotsianidis I, Kastrinaki MC, Papadaki HA. Impaired proliferative potential of bone marrow esenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev. 2014 Jul 15;23(14):1568-81
  32. Diamantopoulos P, Zervakis K, Papadopoulou V, Iliakis T, Kalala F, Giannakopoulou N, Rougala N, **Galanopoulos A**, Bakarakos P, Variami E, Dimitrakopoulou A, Viniou NA. 5-Azacitidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients. Anticancer Res. 2015 Sep;35(9):5141-7.
  33. Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, **Galanopoulos AG**, Kontos CK, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hatjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, Scorilas A, Tsatalas C, Kotsianidis I; Hellenic MDS Study Group. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Clin Cancer Res. 2016 Apr 15;22(8):1958-68
  34. Diamantopoulos PT, Sofotasiou M, Georgoussi Z, Giannakopoulou N, Papadopoulou V, **Galanopoulos A**, Kontandreopoulou E, Zervakis P, Pallaki P, Kalala F, Kyrtsonis MC, Dimitrakopoulou A, Vassilakopoulos T, Angelopoulou M, Spanakis N, Viniou NA.

Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia. *Cancer Med.* 2016 Sep;5(9):2240-8

35. Pappa V, Anagnostopoulos A, Bouronikou E, Briasoulis E, Kotsianidis I, Pagoni M, Zikos P, Tsonos K, Viniou N, Meletis J, Papadaki H, Kioumi A, **Galanopoulos A**, Vervessou EC, Poulakidas E, Karmas P, Karvounis K, Symeonidis A. A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. *Int J Hematol.* 2017 Feb;105(2):184-195
36. Diamantopoulos P, Zervakis K, Zervakis P, Sofotasiou M, Vassilakopoulos T, Kotsianidis I, Symeonidis A, Pappa V, **Galanopoulos A**, Solomou E, Kodandreopoulou E, Papadopoulou V, Korkolopoulou P, Mantzourani M, Kyriakakis G, Viniou NA. Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes. *Blood Cancer J.* 2017 Feb 17;7(2):e533
37. Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, **Galanopoulos AG**, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. *Am J Hematol.* 2018 Jul;93(7):895-901.
38. Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, **Galanopoulos A**, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. *Leuk Res* 2018 Aug;71:55-59.
39. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, **Galanopoulos A**, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. *Hematol Oncol.* 2018 Oct;36(4):693-700.
40. Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, **Galanopoulos A**, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. *Leuk Lymphoma* 2019 Jul;60(7):1721-1730.
41. Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, **Galanopoulos A**, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsolis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. *Ann Hematol* 2019 Jun;98(6):1383-1392.

42. Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, **Galanopoulos A**, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. *Cancer Med* 2019 May;8(5):2056-2063.
43. Kotsianidis I, Papageorgiou SG, Pappa V, **Galanopoulos AG**, Viniou NA, Vassilakopoulos TP, Papoutselis M, Vrachioliass G, Papadopoulos V, Diamantopoulos PT, Tsokanas D, Kourakli A, Symeonidis A. Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). *Mediterr J Hematol Infect Dis* 2019 Jul 1;11(1):e2019045.
44. Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, **Galanopoulos A**, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. *J Geriatr Oncol* 2020 Jan;11(1):121-124.
45. Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, **Galanopoulos A**, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. *Clin Lymphoma Myeloma Leuk*. 2020 Feb;20(2):114-121.
46. Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, Papoutselis M, Vrachioliass G, Pappa V, **Galanopoulos AG**, Vassilakopoulos TP, Hatzimichael E, Zikos P, Papadaki HA, Bouchla A, Panayiotidis P, Megalakaki A, Papaioannou M, Liapis K, Dryllis G, Tsokanas D, Kourakli A, Symeonidis A, Viniou NA, Kotsianidis I. Estimated glomerular filtration rate independently predicts outcome of azacytidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. *Hematol Oncol* 2020 Jun 4. doi: 10.1002/hon.2756. Online ahead of print
47. Liapis K, Vrachioliass G, Papadopoulos V, Kourakli A, **Galanopoulos AG**, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Pontikoglou C, Panayiotidis P, Karakatsanis S, Vardi A, Symeonidis A, Kotsianidis I. Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. *E J Haematol* 2020 Jul 1;11(1):255-261
48. Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, **Galanopoulos A**, Viniou NA, Hatzimichael E, Vassilakopoulos TP, Gogos D, Megalakaki A, Zikos P, Diamantopoulos P, Kourakli A, Giannoulia P, Papoutselis M, Poulakidas E, Arapaki M, Vardi A, Anagnostopoulos A, Mparmparousi D, Papaioannou M, Bouronikou E, Dimou M, Papadaki H, Panayiotidis P, Pappa V. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes

49. Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, **Galanopoulos A**, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtschonis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. *Br J Haematology* 2021 Mar;192(6):978-987
50. Mpakou V, Spathis A, Bouchla A, Tsakiraki Z, Kontsioti F, Papageorgiou S, Bazani E, Gkontopoulos K, Thomopoulos T, Glezou I, **Galanopoulos A**, Symeonidis A, Diamantopoulos PT, Viniou NA, Kontandreopoulou CN, Zafeiropoulou K, Kotsianidis I, Lamprianidou E, Foukas P, Mpamias A, Pappa V. Upregulated hypoxia inducible factor 1 $\alpha$  signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group . *Hematol Oncol* 2021 Apr;39(2):231-242.
51. Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, **Galanopoulos A**, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. *Lancet Haematol* 2021 Feb;8(2):e135-e148.
52. Lamprianidou E, Kordella C, Kazachenka A, Zoulia E, Bernard E, Filia A, Laidou S, Garantziotis P, Vassilakopoulos TP, Papageorgiou SG, Pappa V, **Galanopoulos AG**, Viniou N, Nakou E, Kalafati L, Chatzidimitriou A, Kassiotis G, Papaemmanuil E, Mitroulis I, Kotsianidis I. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacytidine. *Blood Adv.* 2021 Jan 12;5(1):129-142.
53. Liapis K, Papadopoulos V, Vrachiolias G, **Galanopoulos AG**, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Kourakli A, Tsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Pontikoglou C, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Kotsianidis I. Refinement of prognosis and the effect of azacytidine in intermediate-risk myelodysplastic syndromes. *Blood Cancer J.* 2021 Feb 11;11(2):30.
54. Diamantopoulos PT, Stafylidis C, Vlachopoulou D, Kontandreopoulou CN, Giannakopoulou N, Vardaka M, Mpouhla A, Mastrogianni E, Variami E, **Galanopoulos A**, Pappa V, Psychogiou M, Hatzakis A, Viniou NA. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study. *Ther Adv Hematol* 2022;13: 1-12
55. Diamantopoulos PT, Kontandreopoulou CN, Stafylidis C, Vlachopoulou D, Giannakopoulou N, Vardaka M, Mpouhla A, Variami E, **Galanopoulos A**, Pappa V, Psychogiou M, Hatzakis A, Viniou NA. Immunogenicity of a third dose of the BNT162b2

- COVID-19 vaccine in patients with CLL: effects on treatment selection. *Ann Hematol.* 2022 Dec;101(12):2711-2717
56. Diamantopoulos PT, Charakopoulos E, Symeonidis A, Kotsianidis I, Viniou NA, Pappa V, Pontikoglou C, Tsokanas D, Drakos G, Kourakli A, Solomou E, Hatzimichael E, Pouli A, Kotsopoulou M, Asmanis E, Dimou M, Panayiotidis P, Papageorgiou S, Vassilopoulos G, Anagnostopoulos A, Vassilakopoulos T, Papadaki H, **Galanopoulos A**. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. *Sci Rep.* 2022 Oct 26;12(1):17914
57. Kontandreopoulou CN, Diamantopoulos PT, Giannopoulos A, Symeonidis A, Kotsianidis I, Pappa V, **Galanopoulos A**, Panayiotidis P, Dimou M, Solomou E, Loupis T, Zoi K, Giannakopoulou N, Dryllis G, Hatzidavid S, Viniou NA; Hellenic MDS study Group. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. *Leuk Lymphoma* 2022 Mar;63(3):729-73
58. Liapis K, Papadopoulos V, Pontikoglou C, Vrachiolias G, Stavroulaki E, Kourakli A, Lazaris V, **Galanopoulos AG**, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Tsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Papadakis S, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Papadaki HA, Kotsianidis I. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries. *Leukemia.* 2023 Mar;37(3):708-711
59. Bouchla A, Papageorgiou SG, Symeonidis A, Sakellari I, Zikos P, Thomopoulos TP, Hatzimichael E, **Galanopoulos A**, Viniou NA, Kotsianidis I, Pappa V. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome? *Leukemia.* 2023 Dec;37(12):2517-2519
60. Diamantopoulos PT, Solomou E, Symeonidis A, Pappa V, Kotsianidis I, **Galanopoulos A**, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Vassilakopoulos T, Dimou M, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms. *Am J Hematol.* 2023 May;98(5):E119-E122
61. Solomou EE, Kattamis A Prof, Symeonidis A, Sirinian C, Salamaliki C, Tzanoudaki M, Diamantopoulos PT, Plakoula E, Palasopoulou M, Giannakoulas N, Kontandreopoulou CN, Kollia P, Viniou NA, **Galanopoulos A**, Liossis SN, Vassilopoulos G. Increased Age Associated B cells in patients with acquired aplastic anemia correlate with IFN- $\gamma$ . *Blood Adv.* 2023 Nov 27: bloodadvances.2023010109. doi: 10.1182/bloodadvances.2023010109. Online ahead of print.